Artificial intelligence is everywhere. According to GlobalData forecasts, every segment of the AI market is expected to grow in the coming decade and it will be worth around $909 billion by 2030.
As a result, new uses are being discovered for the technology. Drug discovery is no different, and incorporating AI into drug discovery and development has the potential to revolutionise both patient experiences and outcomes. The hope is that AI can revolutionise the drug discovery process and significantly reduce the time and cost of getting a drug to market, particularly in areas of unmet need such as rare diseases or new antibiotics.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.